Tallahassee Memorial HealthCare (TMH) is the first hospital in the region to implant the Surpass Streamline flow diverter device, the newest aneurysm treatment technology. TMH was selected as the first hospital in Florida, outside of the clinical trial, to use the device. On January 25, 2019, Narlin Beaty, MD, and Matthew Lawson, MD, endovascular neurosurgeons, successfully completed three cases in one day – more than any other hospital in the Southeast.
The Surpass Streamline flow diverter is designed to facilitate natural blood flow through the parent blood vessel and away from an aneurysm, a weakness in the vessel wall that can cause hemorrhagic stroke and can affect as many as 1 in 50 people. The Surpass Streamline flow diverter was approved by the Food and Drug Administration (FDA) in July 2018.
“Before this technology, we treated aneurysms, but now we can cure them,” said Narlin Beaty, MD, endovascular neurosurgeon at Tallahassee Memorial. “This new technology can be delivered with more precision than any previous device and actually repairs the wall of the vessel and eliminates blood flow into an aneurysm. Without blood flow, the aneurysm naturally dissipates, eliminating the need to track growth for many years, which could re-occur over time.”
Two commonly used procedures to treat brain aneurysms are surgical clipping and endovascular coiling. Surgical clipping closes off the aneurysm by placing a small metal clip across the neck of the aneurysm, stopping blood from flowing into it. Coiling involves the insertion of soft platinum wires into the aneurysm, causing the blood to clot and create a seal between the artery and the aneurysm. Flow diversion is different from surgical clipping and coiling because it focuses on the diseased part of the vessel that sustains the aneurysm, rather than on the aneurysm itself.
The devices were placed during a minimally invasive procedure in the neurovascular catheterization lab. Dr. Beaty, Dr. Lawson, as well as Dr. T. Adam Oliver are the first three physicians in the region trained to place the Surpass Streamline flow diverter. After the procedure, patients typically stay in the hospital one night and are able to resume normal daily activities within two weeks.
“At TMH, we have been expanding our endovascular program to bring the most advanced procedures possible to our patients,” said Matthew Lawson, MD, endovascular neurosurgeon and Stroke Medical Director at Tallahassee Memorial. “Patients do not need to travel outside of the area for excellent care. In fact, patients across the Southeast travel to TMH to receive these innovative treatments.”